Keywords: hepatitis B, antiviral therapy, pregnancy, lamivudine, entecavir, tenofovir, telbivudine, HBeAg, immunoprophylaxis, effects on the fetus


The aim of the study.Analysis of tactics of antiviral therapy for chronic viral hepatitis b in pregnant women.

Methods. Theoretical analysis of scientific literature; analysis and generalization. Statistics and comparisons. Classification of theoretical material and development of recommendations.

Research results.Today, there are about 2 billion people in the world ill with a chronic infection caused by the hepatitis B virus, 350 million of whom suffer from chronic hepatitis B, and most are asymptomatic carriers of the Australian antigen (HBsAg). Up to 50 % of all new cases of hepatitis B virus infection are due to vertical infection. Despite the lack of increase in viral load during pregnancy, alanine aminotransferase tends to increase in late pregnancy and in the postpartum period. A sharp drop in postpartum corticosteroids may create favourable conditions for hepatitis B virus activation. It is emphasized that the current treatment of hepatitis B virus includes the use of antiviral drugs, where Peg-IFN is absolutely contraindicated in pregnancy, lamivudine and entecavir are classified by the FDA as category C, and tenofovir and telbivudine are classified as category B. During pregnancy, it is recommended to use mainly category B drugs.

Conclusions. The use of antiviral therapy in combination with immunoprophylaxis of new-borns is the optimal strategy for implementation as a universal program, as the success of such an intervention can make a significant contribution to achieving the ultimate goal of global elimination of hepatitis B virus.


Download data is not yet available.

Author Biography

Yuliia Mudra, Shupyk National Medical Academy of Postgraduate Education

Department of Obstetrics, Gynecology and Reproductology



Han, L., Zhang, H. W., Xie, J. X., Zhang, Q., Wang, H. Y., Cao, G. W. (2011). A meta-analysis of lamivudine for interruption of mother-to-child transmission of hepatitis B virus. World Journal of Gastroenterology, 17 (38), 4321–4333. doi:

Bogomolov, P. O., Matsievich, M. V., Kokina, K. Y., Voronkova, N. V., Kuz’mina, O. S., Bueverov, A. O. (2016). Chronic hepatitis b virus infection in pregnancy: strategies of antiviral therapy. Almanac of Clinical Medicine, 6 (40), 126–131. doi:

Han, G.-R., Cao, M.-K., Zhao, W., Jiang, H.-X., Wang, C.-M., Bai, S.-F. et. al. (2011). A prospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection. Journal of Hepatology, 55 (6), 1215–1221. doi:

Gibb, D. M., Kizito, H., Russell, E. C., Chidziva, E., Zalwango, E. et. al. (2012). Pregnancy and Infant Outcomes among HIV-Infected Women Taking Long-Term ART with and without Tenofovir in the DART Trial. PLoS Medicine, 9 (5), e1001217. doi:

Bissinger, A. L., Fehrle, C., Werner, C. R., Lauer, U. M., Malek, N. P., Berg, C. P. (2015). Epidemiology and Genotyping of Patients with Chronic Hepatitis B: Genotype Shifting Observed in Patients from Central Europe. Polish Journal of Microbiology, 64 (1), 15–21. doi:

Han, G. R., Jiang, H. X., Zhao, W., Ge, C. Y., Xu, C. L., Pan, C. (2011). Lamivudine use in the 2nd or 3rd trimester of pregnancy has similar efficacy in preventing vertical transmission of chronic hepatitis B in highly viremic mothers. Hepatology, 54 (S1), 479A.

Pan, C. Q., Mi, L.-J., Bunchorntavakul, C., Karsdon, J., Huang, W. M., Singhvi, G. et. al. (2012). Tenofovir Disoproxil Fumarate for Prevention of Vertical Transmission of Hepatitis B Virus Infection by Highly Viremic Pregnant Women: A Case Series. Digestive Diseases and Sciences, 57 (9), 2423–2429. doi:

Pan, C. Q., Duan, Z., Bhamidimarri, K. R., Zou, H., Liang, X., Li, J., Tong, M. J. (2012). An Algorithm for Risk Assessment and Intervention of Mother to Child Transmission of Hepatitis B Virus. Clinical Gastroenterology and Hepatology, 10 (5), 452–459. doi:

Schillie, S., Walker, T., Veselsky, S., Crowley, S., Dusek, C., Lazaroff, J. et. al. (2015). Outcomes of Infants Born to Women Infected With Hepatitis B. Pediatrics, 135 (5), e1141–e1147. doi:

EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection (2012). Journal of Hepatology, 57 (1), 167–185. doi:

Zhang, H., Pan, C. Q., Pang, Q., Tian, R., Yan, M., Liu, X. (2014). Telbivudine or lamivudine use in late pregnancy safely reduces perinatal transmission of hepatitis B virus in real‐life practice. Hepatology, 60 (2), 468–476. doi:

Pan, C. Q., Duan, Z., Dai, E., Zhang, S., Han, G., Wang, Y. et. al. (2016). Tenofovir to Prevent Hepatitis B Transmission in Mothers with High Viral Load. New England Journal of Medicine, 374 (24), 2324–2334. doi:

Ozaras, R., Inanc Balkan, I., Yemisen, M., Tabak, F. (2015). Epidemiology of HBV subgenotypes D. Clinics and Research in Hepatology and Gastroenterology, 39 (1), 28–37. doi:

👁 61
⬇ 89
How to Cite
Mudra, Y. (2020). THE TACTICS OF ANTIVIRAL THERAPY FOR CHRONIC VIRAL HEPATITIS B IN PREGNANT WOMEN. Technology Transfer: Innovative Solutions in Medicine, 14-16.
Medicine and Dentistry